KJ
Kristi Jones
Chief Executive Officer & President
NexImmuneNexImmune Pipeline
| Drug | Indication | Phase |
|---|
| NEXI-001 | Acute Myeloid Leukemia (post-allo SCT) | Phase 1/2 |
| NEXI-002 | Multiple Myeloma (post-auto SCT) | Phase 1/2 |
| NEXI-003 | HPV-16+ Solid Tumors | Phase 1/2 |